Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Lands New Investors, Funding for Biomarker Development

NEW YORK (GenomeWeb News) – Germany's Kinaxo Biotechnologies said today that it has brought on two new investors and closed a financing round worth an undisclosed amount.

Kinaxo, based in Martinsried, said it will use the funding to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.

Although he declined to disclose the amount of the financing round, Kinaxo CEO Andreas Jenne told GWDN that the company plans to invest €3 million to €4 million ($4.5 million to $5.9 million) in biomarker development over the next two years.

Jenne also said that Kinaxo plans to expand its PhosphoScout phosphoproteomics services, which uses mass spectrometry to investigate phosphorylation events in cellular signal transduction pathways and their response to drug treatment.

New investors Leifina and Conmit Invest joined existing institutional investors Mountain Partners, BioM, High-Tech Gründerfonds, the Max Planck Society, and the KfW ERP Start-Fonds in the financing round, Kinaxo said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.